| Literature DB >> 28458371 |
Suresh Mandava1, Bogonda Ganganna1, Jungjoong Hwang1, Younchang Jang1, Jiho Hwang1, Mallesham Samala1, Ki-Bbeum Kim1, Haeil Park1, Ji Hyun Lee2, Sun Young Baek2, Jongkook Lee1.
Abstract
A number of phosphodiesterase 5 (PDE5) inhibitors approved by authorities have been used successfully in the treatment of erectile dysfunction. These medicines must be prescribed carefully due to their adverse effects, but they and their analogues are being illegally added to dietary supplements. These illegal dietary supplements pose a significant risk to public health. Several dimeric tadalafil analogues have been synthesized for use as reference standards in the inspection of functional foods that are mainly advertised as sexual enhancement products. During the course of this synthesis, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) was proven to be the reagent of choice for amide coupling to produce these dimeric tadalafil analogues. Moreover, the trans-isomer structures tentatively assigned for the isolated dimeric tadalafil analogues (bisprehomotadalafil and bisprecyclopentyltadalafil) found in dietary supplements are now revised to cis-isomer structures.Entities:
Keywords: bisprecyclopentyltadalafil; bisprehomotadalafil; bisprenortadalafil; dietary supplement; phosphodiesterase 5 inhibitor
Mesh:
Substances:
Year: 2017 PMID: 28458371 DOI: 10.1248/cpb.c17-00034
Source DB: PubMed Journal: Chem Pharm Bull (Tokyo) ISSN: 0009-2363 Impact factor: 1.645